Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders
Authors:
- 12 September 2020
- journal article
- research article
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 21, e927418-1-e927418-4
Abstract
BACKGROUND:Patients receiving immunosuppressive therapies might be more susceptible to COVID-19. Conversely, an exaggerated inflammatory response to the SARS-CoV-2 infection might be blunted by certain forms of immunosuppression, which could be protective. Indeed, there are data from animal models demonstrating that complement may be a part of the pathophysiology of coronavirus infections. There is also evidence from an autopsy series demonstrating complement deposition in the lungs of patients with COVID-19. This raises the question of whether patients on anti-complement therapy could be protected from COVID-19. CASE REPORT:Case 1 is a 39-year-old woman with an approximately 20-year history of paroxysmal nocturnal hemoglobinuria (PNH), who had recently been switched from treatment with eculizumab to ravulizumab prior to SARS-CoV-2 infection. Case 2 is a 54-year-old woman with a cadaveric renal transplant for lupus nephritis, complicated by thrombotic microangiopathy, who was maintained on eculizumab, which she started several months before she developed the SARS-CoV-2 infection. Case 3 is a 60-year-old woman with a 14-year history of PNH, who had been treated with eculizumab since 2012, and was diagnosed with COVID-19 at the time of her scheduled infusion. All 3 patients had a relatively mild course of COVID-19. CONCLUSIONS:We see no evidence of increased susceptibility to SARS-CoV-2 in these patients on anti-complement therapy, which might actually have accounted for the mild course of infection. The effect of anti-complement therapy on COVID-19 disease needs to be determined in clinical trials.Keywords
This publication has 9 references indexed in Scilit:
- The case of complement activation in COVID-19 multiorgan impactKidney International, 2020
- The first case of COVID-19 treated with the complement C3 inhibitor AMY-101Clinical Immunology, 2020
- Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five casesTranslational Research, 2020
- Complement as a target in COVID-19?Nature Reviews Immunology, 2020
- Coronaviruses hijack the complement systemNature Reviews Immunology, 2020
- Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience2020
- Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus PathogenesismBio, 2018
- Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4 -transgenic mice infected with MERS-CoVEmerging Microbes & Infections, 2018
- Interactions between coagulation and complement—their role in inflammationSeminars in Immunopathology, 2011